What melanoma is and why it matters
Melanoma is an aggressive form of skin cancer that begins in melanocytes, the pigment-producing cells responsible for skin color. While it accounts for a small share of skin cancers, melanoma causes the majority of skin cancer deaths because it is more likely to spread if not caught early. When identified and treated in localized stages, outcomes are often excellent; advanced or metastatic melanoma requires systemic, long-term management. Understanding the causes, warning signs, and proven prevention strategies helps people make informed decisions about screening, sun safety, and timely care.
Risk factors and prevention
Ultraviolet exposure and other triggers
Exposure to ultraviolet (UV) radiation from the sun or artificial sources such as tanning beds is the primary preventable risk factor. UV exposure damages DNA in skin cells, and accumulated mutations can lead to melanoma. Risk is higher with intense intermittent sun exposure and sunburn, especially in childhood. Other factors include many moles (particularly atypical moles), fair skin that burns easily, a personal or family history of melanoma or other skin cancers, immunosuppression, and certain genetic syndromes. While these risks increase probability, melanoma can occur in people without known risk factors, underscoring the importance of vigilance for everyone.
Practical prevention strategies
- Use broad-spectrum sunscreen with SPF 30 or higher, reapplying every two hours and after swimming or sweating.
- Seek shade during peak sun hours (roughly 10 a.m. to 4 p.m.), and wear protective clothing, wide-brimmed hats, and UV-blocking sunglasses.
- Avoid tanning beds entirely; there is no safe level of artificial UV exposure.
- Perform regular skin self-exams and schedule professional skin checks, especially if you have many moles or a family history of melanoma.
Detecting melanoma: the ABCDE rule and beyond
Early detection significantly improves outcomes. Clinicians and patients use the ABCDE criteria to spot suspicious lesions, but they are one tool among many. Any changing, new, or unusual mark on the skin warrants professional evaluation.
ABCDE criteria overview
| Feature | What to look for | Why it matters |
|---|---|---|
| A — Asymmetry | One half does not match the other | Symmetry is common in benign moles |
| B — Border | Irregular, scalloped, or poorly defined edges | Benign lesions typically have smooth borders |
| C — Color | Varied shades of brown, black, tan, red, white, or blue | Uniform color is usually reassuring |
| D — Diameter | Often larger than 6 mm (about the size of a pencil eraser), though melanomas can be smaller | Size alone is insufficient for ruling out melanoma |
| E — Evolving | Changes in size, shape, color, elevation, or symptoms such as bleeding or itching | Evolution is the most sensitive warning sign |
Additional warning signs
- The ‘Ugly Duckling’ sign: a lesion that looks notably different from others on your body.
- New lesions in adulthood, especially after age 30.
- Sores that do not heal, persistent oozing or crusting, or new pigmentary changes in the nail bed (dark streaks or banding).
Melanoma subtypes and what they mean
Melanoma is not a single disease; subtypes behave differently and may arise in distinct locations. Recognizing these patterns helps clinicians choose the most appropriate treatment and informs prognosis.
Common subtypes overview
- Superficial spreading melanoma: the most common subtype in lighter-skinned populations, often starting as a flat patch with irregular borders and varied color.
- Nodular melanoma: tends to grow vertically more quickly; may appear as a raised bump and can be darker or even amelanotic (lacking pigment).
- Lentigo maligna melanoma: arises in sun-damaged skin, often on the face or arms of older adults; it grows slowly and has a better prognosis when treated early.
- Acral lentiginous melanoma: occurs on palms, soles, or under nails; more common in people with darker skin and can be harder to detect early.
Staging and how it guides treatment
Staging describes how far melanoma has spread and is fundamental to treatment planning. It is based on tumor thickness (Breslow depth), presence of ulceration, lymph node involvement, and distant metastasis. Earlier-stage disease is often treated with local excision, while advanced stages may require more extensive approaches.
Stage at diagnosis overview
| Stage | Key features | Typical approach |
|---|---|---|
| Stage 0 — Melanoma in situ | Malignant cells confined to the epidermis | Wide local excision with clear margins |
| Stage I — II | Localized disease; variable tumor thickness and ulceration | Surgical excision; sentinel lymph node biopsy may be considered based on risk |
| Stage III | Spread to regional lymph nodes or nearby structures | Surgery plus adjuvant systemic therapy (e.g., immunotherapy or targeted therapy) considered based on risk |
| Stage IV | Distant metastasis to organs such as lung, liver, brain, or bone | Systemic therapies including immunotherapy, targeted therapy, clinical trials, and supportive care |
Prognostic factors at a glance
- Breslow thickness: the deeper the tumor, the higher the risk of spread.
- Ulceration: presence worsens prognosis but does not preclude cure with appropriate treatment.
- Lymph node involvement: more involved nodes or extracapsular extension correlates with higher recurrence risk.
- Mitotic rate and genomic alterations (e.g., BRAF V600E) can inform behavior and treatment options.
Treatment options and advances
The treatment of melanoma has transformed dramatically, especially for advanced disease. Decisions are individualized based on stage, subtype, genomic profile, and patient health. Multidisciplinary care involving dermatology, oncology, surgery, and pathology ensures coordinated management.
Localized and regional disease
For early-stage melanoma, wide local excision to remove the tumor with a margin of normal tissue is standard. For thicker tumors or those with higher-risk features, sentinel lymph node biopsy may be performed to assess microscopic spread. Additional regional treatments may include radiation in select scenarios.
Advanced melanoma therapies
- Immunotherapy: drugs such as PD-1 inhibitors (e.g., pembrolizumab, nivolumab) and CTLA-4 inhibitors (e.g., ipilimumab) can produce durable responses by helping the immune system recognize and attack cancer cells.
- Targeted therapy: for melanomas with specific driver mutations (most commonly BRAF V600E or V600K), targeted agents (e.g., dabrafenib, trametinib) can shrink tumors quickly, often used in combination approaches.
- Surgery and radiation: complete resection of residual or isolated metastases may be beneficial in selected cases; stereotactic body radiation or focused treatments address specific problem areas.
- Clinical trials: emerging approaches, including cancer vaccines, T-cell therapies, and novel combinations, offer additional options, particularly when standard therapies are not effective or stop controlling disease.
Follow-up, survivorship, and when to seek care
Regular follow-up is an essential part of melanoma care. Visits often include a full skin exam, regional lymph node check, and discussion of any new symptoms. The frequency of visits typically decreases over time if no concerns arise but should remain tailored to the individual’s risk. Survivors should practice lifelong sun protection and avoid tanning beds. Any new or changing skin mark, persistent cough, unexplained weight loss, bone pain, or neurologic changes should prompt prompt medical evaluation, as these can signal recurrence or secondary issues.
Living well after melanoma: practical takeaways
- Schedule regular professional skin exams and perform monthly self-skin checks.
- Adopt consistent sun-protective behaviors: sunscreen, clothing, shade, and avoiding peak UV times.
- Understand your subtype, stage, and genomic profile so you know your recurrence risks and treatment options.
- Discuss survivorship care plans with your oncology team, including timelines for imaging and labs when relevant.
- Seek psychosocial support if needed; a cancer diagnosis can affect mental health and relationships.
When to contact a clinician
If you find a suspicious or changing skin lesion or have a personal history of melanoma with new symptoms, contact a dermatologist or primary care clinician promptly. For known stage III or IV melanoma, coordinate closely with your oncology team about scans, symptom management, and treatment timing. Early assessment of worrisome changes supports the best possible outcomes and quality of life.